CATALOGO DEI PRODOTTI DELLA RICERCA

CORBO, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.840
NA - Nord America 5.164
AS - Asia 4.403
SA - Sud America 651
AF - Africa 109
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 2
Totale 17.205
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.029
RU - Federazione Russa 2.824
SG - Singapore 1.758
CN - Cina 1.407
GB - Regno Unito 1.259
IT - Italia 899
BR - Brasile 537
HK - Hong Kong 521
DE - Germania 386
IE - Irlanda 297
SE - Svezia 295
VN - Vietnam 291
FR - Francia 268
FI - Finlandia 197
NL - Olanda 116
KR - Corea 102
CA - Canada 66
AT - Austria 62
IN - India 57
UA - Ucraina 55
ES - Italia 45
JP - Giappone 45
AR - Argentina 38
ID - Indonesia 36
MX - Messico 36
AU - Australia 31
PL - Polonia 30
TR - Turchia 29
BD - Bangladesh 27
BE - Belgio 27
TG - Togo 24
ZA - Sudafrica 24
IQ - Iraq 21
CO - Colombia 20
BJ - Benin 18
EC - Ecuador 17
MA - Marocco 16
IR - Iran 15
CZ - Repubblica Ceca 14
LT - Lituania 14
PY - Paraguay 12
UZ - Uzbekistan 12
VE - Venezuela 11
JO - Giordania 10
SA - Arabia Saudita 10
CH - Svizzera 9
PK - Pakistan 8
CR - Costa Rica 7
JM - Giamaica 7
IL - Israele 6
TN - Tunisia 6
AL - Albania 5
AZ - Azerbaigian 5
CL - Cile 5
KE - Kenya 5
KG - Kirghizistan 5
MY - Malesia 5
NP - Nepal 5
NZ - Nuova Zelanda 5
PE - Perù 5
PT - Portogallo 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
EG - Egitto 4
HN - Honduras 4
NI - Nicaragua 4
PA - Panama 4
RS - Serbia 4
BO - Bolivia 3
DK - Danimarca 3
DZ - Algeria 3
LV - Lettonia 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BN - Brunei Darussalam 2
CI - Costa d'Avorio 2
EE - Estonia 2
ET - Etiopia 2
HU - Ungheria 2
KZ - Kazakistan 2
LK - Sri Lanka 2
NO - Norvegia 2
OM - Oman 2
RO - Romania 2
SN - Senegal 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AD - Andorra 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
CU - Cuba 1
FK - Isole Falkland (Malvinas) 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
Totale 17.192
Salva come PNG Salva come JPEG
Città #
Southend 1.100
Moscow 959
Singapore 812
Chandler 706
Dallas 604
Hong Kong 507
Ashburn 471
Verona 379
Beijing 306
Dublin 282
Jacksonville 235
Ann Arbor 220
Woodbridge 206
New York 181
Los Angeles 132
Munich 129
The Dalles 125
Jinan 107
Lawrence 97
Princeton 97
Wilmington 91
Houston 90
Redmond 83
Ho Chi Minh City 79
Shenyang 69
Nanjing 67
São Paulo 60
Redondo Beach 59
Hanoi 58
Helsinki 57
Turku 50
Hebei 49
Tianjin 47
Santa Clara 46
Columbus 43
London 41
Sindelfingen 41
Zhengzhou 40
Buffalo 39
Milan 39
Haikou 38
Tokyo 37
Vienna 37
Changsha 35
Ningbo 34
Dearborn 33
Denver 33
Seattle 33
Brooklyn 31
Hangzhou 31
Nuremberg 31
Council Bluffs 29
Dong Ket 28
Warsaw 28
Brussels 27
Amsterdam 26
Orem 25
Stockholm 25
Bologna 24
Jakarta 24
Lappeenranta 24
Lomé 24
San Francisco 24
Taiyuan 24
Frankfurt am Main 22
Guangzhou 22
Redwood City 22
Boardman 21
Poplar 21
Chicago 20
Madrid 20
Taizhou 20
Nanchang 19
Chennai 18
Cotonou 18
Montreal 18
Falkenstein 17
Jiaxing 17
Rome 17
Norwalk 16
Phoenix 16
Toronto 16
Ankara 15
Brescia 15
Haiphong 15
Manchester 15
Seoul 15
Washington 15
Johannesburg 14
Kent 14
Mexico City 14
Rio de Janeiro 14
Atlanta 13
Boston 12
Cagliari 12
Curitiba 11
Lanzhou 11
Sydney 11
Tashkent 11
Baghdad 10
Totale 10.085
Salva come PNG Salva come JPEG
Nome #
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 260
MAP Kinase inhibition reshapes tumour microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages 257
Whole-genome landscape of pancreatic neuroendocrine tumours 252
DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples 236
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 223
Genomic analyses identify molecular subtypes of pancreatic cancer 217
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. 212
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations 212
Unraveling the role of lymph node metastasis in PDAC and dCCA progression 206
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 194
RON is not a prognostic marker for resectable pancreatic cancer 189
MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases 184
Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation 182
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 182
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 178
Reporting tumor molecular heterogeneity in histopathological diagnosis 176
PD-1, PD-L1 and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications 175
Complete neural stem cell (nsc) neuronal differentiation requires a branched chain amino acids-induced persistent metabolic shift towards energy metabolism 172
Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data 172
Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer 170
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 164
Lost in translation: returning germline genetic results in genome-scale cancer research 163
Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract. 160
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 160
Molecular biology of neuroendocrine tumors 159
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer 158
Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers 158
Hypermutation In Pancreatic Cancer 157
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 157
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer 157
Cell Lineage Infidelity in PDAC Progression and Therapy Resistance 157
Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC 156
Comparative Lesions Analysis Through a Targeted Sequencing Approach 156
Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation 155
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma 155
Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer 155
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 154
Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice 153
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 152
Combinatorial Effect of Magnetic Field and Radiotherapy in PDAC Organoids: A Pilot Study 150
Mutational analysis of cancer candidate genes in different pancreatic cancer types 149
Fhit down-regulation is an early event in pancreatic carcinogenesis 149
Pancreatic cancer genomics 149
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models 149
Molecular Pathology of Pancreatic Cancer: from bench-to-bedside translation. 147
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas 145
CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan 145
Exosomal miRNA signatures of pancreatic lesions 144
Next-Generation Histopathologic Diagnosis: A Lesson From a Hepatic Carcinosarcoma 143
ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance 142
Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis 142
Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients 142
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 140
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. 138
Molecular alterations in basal cell carcinoma subtypes 138
Loss of FGFR4 promotes the malignant phenotype of PDAC 136
Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries 136
Combinatorial Effect of Magnetic Field and Radiotherapy in Pancreatic Ductal Adenocarcinoma Organoids 135
Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium 133
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 133
Profiling mTOR pathway in neuroendocrine tumors. 132
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 132
Generation of Pancreatic Organoid-Derived Isografts 131
Author Correction: The landscape of viral associations in human cancers 130
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 130
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing 129
Sex differences in oncogenic mutational processes 128
Divergent mutational processes distinguish hypoxic and normoxic tumours 127
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes 127
Whole genomes redefine the mutational landscape of pancreatic cancer 125
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer 124
Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma 124
Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer 123
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer 123
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples 123
Muscle derangement and alteration of the nutritional machinery in NSCLC 122
Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling 121
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association 121
Update on the molecular pathogenesis of pancreatic tumors other than common ductal adenocarcinoma 119
Mutational profile of GNAQQ209 in human tumors 119
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer 117
Local ablation disrupts immune evasion in pancreatic cancer 115
Long-term organoid culture of a small intestinal neuroendocrine tumor 114
Profiling mTOR pathway in neuroendocrine tumors 113
Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of rapamycin in pancreatic endocrine tumour cells 113
Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas 112
Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC 111
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer 111
Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care 110
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer 110
Preclinical Modelling of PDA: Is Organoid the New Black? 108
Current role of non-coding RNAs in the clinical setting 107
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 107
Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward 105
Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characterization 104
MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC 103
Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer 103
Comprehensive molecular characterization of mitochondrial genomes in human cancers 101
Combined burden and functional impact tests for cancer driver discovery using DriverPower 100
Modeling Cell Communication in Cancer With Organoids: Making the Complex Simple 100
Totale 14.694
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.446
article - articoli 55.111
book - libri 0
conference - conferenze 2.163
curatela - curatele 0
other - altro 1.905
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.267
Totale 120.892
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021345 0 0 0 0 0 84 23 23 28 25 79 83
2021/2022979 95 311 33 50 39 37 29 58 35 16 76 200
2022/20231.889 113 222 150 328 160 453 23 115 230 19 41 35
2023/20241.225 43 76 78 106 139 211 61 144 29 85 186 67
2024/20253.647 179 161 177 529 201 179 245 216 524 251 373 612
2025/20266.448 691 491 705 1.582 2.524 455 0 0 0 0 0 0
Totale 17.524